Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors

Journal of Virology

Volumn 78, Issue 17, 2004, Pages 9352-9365

  Diwan, Prerna ^a,c   Lacasse, Jonathan J ^a   Schang, Luis M ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b 315C Her Medical Research Center ^*  (Canada)

^c UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOHEXIMIDE; DACTINOMYCIN; ROSCOVITINE; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; VERO CELL; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; GENOME; GENOME, VIRAL; GENOMICS; HERPESVIRUS 1, HUMAN; IMMEDIATE-EARLY PROTEINS; PROMOTER REGIONS (GENETICS); PURINES; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; VERO CELLS;

EID: 4143120023     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.17.9352-9365.2004     Document Type: Article

References (87)

1. Advani, S. J., R. Hagglund, R. R. Weichselbaum, and B. Roizman. 2001. Posttranslational processing of infected cell Proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. J. Virol. 73:7904-7912.
2. Advani, S. J., R. R. Weichselbaum, and B. Roizman. 2001. cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 UL42 DNA synthesis processivity factor. J. Virol. 75:10326-10333.
3. Advani, S. J., R. R. Weichselbaum, and B. Roizman. 2000. The role of cdc2 in the expression of herpes simplex virus genes. Proc. Natl. Acad. Sci. USA 97:10996-11001.
4. Bain, J., H. McLauchlan, M. Elliott, and P. Cohen. 2003. The specificities of protein kinase inhibitors: an update. Biochem. J. 371:199-204.
5. Batterson, W., and B. Roizman. 1983. Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J. Virol. 46:371-377.
6. Bhattacharjee, R. N., G. C. Banks, K. W. Trotter, H. L. Lee, and T. K. Archer. 2001. Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol. Cell. Biol. 21:5417-5425.
7. Boutell, C., S. Sadis, and R. D. Everett. 2002. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76:841-850.
8. Bresnahan, W. A., I. Boldogh, P. Chi, E. A. Thompson, and T. Albrecht. 1997. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 231:239-247.
9. Bresnahan, W. A., I. Boldogh, E. A. Thompson, and T. Albrecht. 1996. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 224:150-160.
10. Buolamwini, J. K. 2000. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 6:379-392.
11. cdc2 are inhibited in human lymphoid cells arrested in G1 by alpha-interferon. Biochim. Biophys. Acta 1137:73-76.
12. Carlson, B. A., M. M. Dubay, E. A. Sausville, L. Brizuela, and P. J. Worland. 1996. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:2973-2978.
13. Chao, S. H., K. Fujinaga, J. E. Marion, R. Taube, E. A. Sausville, A. M. Senderowicz, B. M. Peterlin, and D. H. Price. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275:28345-28348.
14. Chao, S. H., and D. H. Price. 2001. Flavopiridol inactivates p-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276:31793-31799.
15. Chao, S. H., J. R. Walker, S. K. Chanda, N. S. Gray, and J. S. Caldwell. 2003. Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus. Mol. Cell. Biol. 23:831-841.
16. Cismowski, M. J., G. M. Laff, M. J. Solomon, and S. I. Reed. 1995. KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae but lacks cyclin-dependent kinase-activating kinase (CAK) activity. Mol. Cell. Biol: 15:2983-2992.
17. Coen, D. M., and P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discovery 2:278-288.
18. Davido, D. J., D. A. Leib, and P. A. Schaffer. 2002. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0. J. Virol. 76:1077-1088.
19. Davido, D. J., W. F. Von Zagorski, G. G. Maul, and P. A. Schaffer. 2003. The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0. J. Virol. 77:12603-12616.
20. de la Fuente, C., A. Maddukuri, K. Kehn, S. Y. Baylor, L. Deng, A. Pumfery, and F. Kashanchi. 2003. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr. HIV Res. 1:131-152.
21. Everett, R. D., and G. G. Maul. 1994. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13:5062-5069.
22. Everett, R. D., M. Meredith, A. Orr, A. Cross, M. Kathoria, and J. Parkinson. 1997. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519-1530.
23. Fax, P., O. Lehmkuhler, C. Kuhn, H. Esche, and D. Brockmann. 2000. E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP. J. Biol. Chem. 275:40554-40560.
24. Fischer, P. M. 2003. CDK versus GSK-3 inhibition. A purple haze no longer? Chem. Biol. 10:1144-1146.
25. Fischer, P, M., and A. Gianella-Borradori. 2003. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 12:955-970.
26. Fisher, P., J. Endicott, and L. Meijer. 2003. Cyclin-dependent kinase inhibitors, p. 235-248. In L. Meijer, A. Jézequel, and M. Roberge (ed.), Progress in cell cycle research, vol. 5. Life in progress, Roscoff, France.
27. Gebara, M. M., M. H. Sayre, and J. L. Corden. 1997. Phosphorylation of the carboxy-terminal repeat domain in RNA polymerase II by cyclin-dependent kinases is sufficient to inhibit transcription. J. Cell Biochem. 64:390-402.
28. Gherardi, D., V. D'Agati, T.-H. T. Chu, A. Barnett, A. Gianella-Borradori, I. H. Gelman, and P. J. Nelson. 2004. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J. Am. Soc. Nephrol. 15:1212-1222.
29. Gray, N. S., L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S. H. Kim, D. J. Lockhart, and P. G. Schultz. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538.
30. Hirst, M., M. S. Kobor, N. Kuriakose, J. Greenblatt, and J. Sadowski. 1999. GAL4 is regulated by the RNA polymerase II holoenzyme-associated cyclin-dependent protein kinase SRB10/CDK8. Mol. Cell 3:673-678.
31. Hooijberg. J. H., H. J. Broxterman, M. Heijn, D. L. Fles, J. Lankelma, and H. M. Pinedo. 1997. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 413:344-348.
32. Jordan, R., and P. A. Schaffer. 1997. Activation of gene expression by herpes simplex virus type 1 ICP0 occurs at the level of mRNA synthesis. J. Virol. 71:6850-6862.
33. Jordan, R., L. Schang, and P. A. Schaffer. 1999. Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. J. Virol. 73:8843-8847.
34. Kawaguchi, Y., C. VanSant, and B. Roizman. 1997. Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3. J. Virol. 71:7328-7336.
35. Koop, K. E., J. Duncan, and J. R. Smiley. 1993. Binding sites for the herpes simplex virus immediate-early protein ICP4 impose an increased dependence on viral DNA replication on simple model promoters located in the viral genome. J. Virol. 67:7254-7263.
36. Kouroukis, C. T., A. Belch, M. Crump, E. Eisenhauer, R. D. Gascoyne, R. Meyer, R, Lohmann, P. Lopez, J. Powers, R. Turner, and J. M. Connors. 2003. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 21:1740-1745.
37. Krude, T. 2000. Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. J. Biol. Chem. 275:13699-13707.
38. Kudoh, A., T. Daikoku, Y. Sugaya, H. Isomura, M. Fujita, T. Kiyono, Y. Nishiyama, and T. Tsurumi. 2004. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing Viral lytic replication. J. Virol. 78:104-115.
39. Lam, L., O. Pickeral, A. Peng, A. Rosermald, E. Hurt, J. Giltnane, L. Averett, H. Zhao, R. Davis, M. Sathyamoorthy, L. Wahl, E. Harris, J. Mikovits, A. Monks, M. Hollingshead, E. Sansville, and L. Staudt. 2001. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2:0041.0041-0041.0011.
40. Laurence, V., S. Faivre, K. Vera, J. Pierga, C. Delbaldo, M. Bekradda, J. Armand, A. Gianella-Borradori, V. Dieras, and E. Raymond. 2002. Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies. Eur. J. Cancer 38(Suppl. 7):49.
41. Leclerc, S., M. Garnier, R. Hoessel, D. Marko, J. A. Bibb, G. L. Snyder, P. Greengard, J. Biernat, Y.-Z. Wu, E.-M. Mandelkow, G. Eisenbrand, and L. Meijer. 2000. Indirubins inhibit glycogen synthase kinase-3beta and CDK5/ p25, two protein kinases involved in abnormal Tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276:251-260.
42. Leresche, A., V. J. Wolf, and J. M. Gottesfeld. 1996. Repression of RNA polymerase II and III transcription during M phase of the cell cycle. Exp. Cell Res. 229:282-288.
43. Losiewicz, M. D., B. A. Carlson, G. Kaur, E. A. Sausville, and P. J. Worland. 1994. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:589-595.
44. Mackem, S., and B. Roizman. 1982. Structural features of the herpes simplex virus alpha gene 4, 0, and 27 promoter-regulatory sequences which confer alpha regulation on chimeric thymidine kinase genes. J. Virol. 44:939-949.
45. Majello, B., G. Napolitano, A. Giordano, and L. Lania. 1999. Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo. Oncogene 18:4598-4605.
46. Mandal, M., D. Bandyopadhyay, T. M. Goepfert, and R. Kumar. 1998. Interferon induces expression of cyclin-dependent kinase inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16:217-225.
47. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
48. Marshall, N. F., J. Peng, Z. Xic, and D. H. Price. 1996. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. 271:27176-27183.
49. Marshall, N. F., and D. H. Price. 1995. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol Chem. 270:12335-12338.
50. Meijer, L., A. Borgne, O. Mulner, J. P. Chong, J. J. Blow, N. Inagaki, M. Inagaki, J. G. Delcros, and J. P. Moulinoux. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Euro. J. Biochem. 243:527-536.
51. Meijer, L., and E. Damiens. 2002. CDK inhibitors: Small molecular weight compounds, p. 145-162. In H. Maruta (ed.), Tumor suppressing viruses, genes and drugs: innovative cancer therapy approaches. Academic Press, Inc., New York, N.Y.
52. Meijer, L., S. Leclerc, and M. Leost. 1999. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 82:279-284.
53. Moffat, J., M. McMichael, S. Leisenfelder, and S. Taylor. 2004. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim. Biophys. Acta 1697:225-231.
54. Mossman, K. L., H. A. Saffran, and J. R. Smiley. 2000. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J. Virol. 74:2052-2056.
55. Nelson, P. J., V. D. D'Agati, J.-M. Gries, J.-R. Suarez, and I. H. Gelman. 2003. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor, flavopiridol. J. Antimicrob. Chemother. 51:921-929.
56. Nelson, P. J., I. H. Gelman, and P. E. Klotman. 2001. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J. Am. Soc. Nephrol. 12:2827-2831.
57. Nicholl, M. J., and C. M. Preston. 1996. Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific. J. Virol. 70:6336-6339.
58. Oikonomakos, N. G., J. B. Schnier, S. E. Zographos, V. T. Skamnaki, K. E. Tsitsanou, and L. N. Johnson. 2000. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275:3456-34573.
59. Orberg, P. K., and P. A. Schaffer. 1987. Expression of herpes simplex virus type 1 major DNA-binding protein, ICP8, in transformed cell line: complementation of deletion mutants and inhibition of wild-type virus. J. Virol. 61:1136-1146.
60. Panagiotidis, C. A., and S. J. Silverstein. 1999. The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Virology 256:64-74.
61. Panning, B., and J. R. Smiley. 1989. Regulation of cellular genes transduced by herpes simplex virus. J. Virol. 63:1929-1937.
62. Pasick, J. M., and J. R. Smiley. 1988. Regulated expression of stably transfected herpes simplex virus thymidine kinase genes in continuous cell lines expressing a temperature-sensitive mutant form of the immediate-early protein ICP4. Virology 162:490-493.
63. Peng, J., N. F. Marshall, and D. H. Price. 1998. Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J. Biol. Chem. 273:13855-13860.
64. Rice, S. A., M. C. Long, V. Lam, P. A. Schaffer, and C. A. Spencer. 1995. Herpes simplex virus immediate-early protein ICP22 is required for viral modification of host RNA polymerase II and establishment of the normal viral transcription program. J. Virol. 69:5550-5559.
65. Sadaie, M. R., R. Mayner, and J. Doniger. 2004. A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics. Antiviral Res. 61:1-18.
66. Sangfelt, O., S. Erickson, S. Einhorn, and D. Grander. 1997. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene 14:415-423.
67. Satomoto, K., M. Haisa, Y. Naomoto, N. Tanaka, and K. Orita. 1995. Cyclin A and Cdk2 kinase activity are suppressed by combined treatment with tumor necrosis factor-alpha and interferon-alpha. Biochem. Biophys. Res. Commun. 213:1115-1121.
68. Schang, L., G.-J. Hwang, B. Dynlacht, D. Speicher, A. Bantly, P. Schaffer, A. Shelatifard, H. Ge, and R. Shiekhattar. 2000. Human PC4 is a substratespecific inhibitor of RNA Polymerase II phosphorylation. J. Biol. Chem. 275:6071-6074.
69. Schang, L. M. 2002. Cyclin dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50:779-792.
70. Schang, L. M. 2004. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim. Biophys. Acta 1697:197-209.
71. Schang, L. M., A. Bantly, and P. A. Schaffer. 2002. Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdks2 and 4. J. Virol. 76:7724-7735.
72. Schang, L. M., A. Bantly, M. Knockaert, F. Shaheen, L. Meijer, M. Malim, N. Gray, and P. A. Schaffer. 2002. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of HSV and HIV-1 by targeting cellular, not viral, proteins. J. Virol. 76:7874-7882.
73. Schang, L. M., J. Phillips, and P. A. Schaffer. 1998. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72:5626-5637.
74. Schang, L. M., A. Rosenberg, and P. A. Schaffer. 2000. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74:2107-2120.
75. Schang, L. M., A. Rosenberg, and P. A. Schaffer. 1999. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. 73:2161-2172.
76. Serizawa, H., T. P. Makela, J. W. Conaway, R. C. Conaway, R. A. Weinberg, and R. A. Young. 1995. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 374:280-282.
77. Shiekhattar, R., F. Mermelstein, R. P. Fisher, R. Drapkin, B. Dynlacht, H. C. Wessling, D. O. Morgan, and D. Reinberg. 1995. Cdk-activating kinase complex is a component of human transcription factor. Nature 374:283-287.
78. Smibert, C. A., and J. R. Smiley. 1990. Differential regulation of endogenous and transduced beta-globin genes during infection of erythroid cells with a herpes simplex virus type 1 recombinant. J. Virol. 64:3882-3894.
79. Smiley, J. R., C. Smibert, and R. D. Everett. 1987. Expression of a cellular gene cloned in herpes simplex virus: rabbit beta-globin is regulated as an early viral gene in infected fibroblasts. J. Virol. 61:2368-2377.
80. Smith, C. A., P. Bates, R. Rivera-Gonzalez, B. Gu, and N. A. DeLuca. 1993. ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB. J. Virol. 67:4676-4687.
81. Spencer, C. A., M. E. Dahnius, and S. A. Rice. 1997. Repression of host RNA polymerase II transcription by herpes simplex virus type 1. J. Virol. 71:2031-2040.
82. Sun, X., Y. Zhang, H. Cho, P. Rickert, E. Lees, W. Lane, and D. Reinberg. 1998. NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription. Mol. Cell 2:213-222.
83. Taylor, S. L., P. R. Kinchington, A. Brooks, and J. F. Moffat. 2004. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicellazoster virus. J. Virol. 78:2853-2862.
84. Vesely, J., L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J. Kato, L. Detivaud, S. Leclerc, et al. 1994. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224:771-786.
85. Wang, D., C. de la Fuente, L. Deng, L. Wang, I. Zilberman, C. Eadie, M. Healey, D. Stein, T. Denny, L. E. Harrison, L. Meijer, and F. Kashanchi. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75:7266-7279.
86. Wang, L., L. Deng, K. Wu, C. de la Fuente, D. Wang, K. Kehn, A. Maddukuri, S. Baylor, F. Santiago, E. Agbottah, S. Trigon, M. Morange, R. Mahieux, and F. Kashanchi. 2002. Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors. Mol. Cell. Biochem. 237:137-153.
87. Workman, J. L., and R. E. Kingston. 1998. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu. Rev. Biochem. 67:545-579.